首页> 外文期刊>The Journal of Thoracic and Cardiovascular Surgery >Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit
【24h】

Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit

机译:重症监护室心胸外科手术后对肝素诱导的血小板减少症的认识和阿加曲班治疗的开始

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: Patients recovering from cardiothoracic surgery are known to be at increased risk of heparin-induced thrombocytopenia. Postoperatively, if heparin-induced thrombocytopenia is suspected, heparin is discontinued immediately and an alternative anticoagulant, such as the direct thrombin inhibitor argatroban, is administered. Current data regarding the safety and efficacy of argatroban in the postoperative cardiothoracic surgical patient in the intensive care setting are limited. Methods: Data were collected retrospectively from January 1, 2007, to December 31, 2010, from patients tested for antiplatelet factor 4/heparin antibodies on clinical suspicion of heparin-induced thrombocytopenia after cardiothoracic surgery. We evaluated the use of argatroban as a therapeutic agent for the postoperative treatment of suspected heparin-induced thrombocytopenia by comparing thrombotic and bleeding events, platelet dynamics, antiplatelet factor 4/heparin antibody titer, and clinical probability score between patients who did and did not receive argatroban. Results: Eighty-seven patients were included; 47 patients (54%) were treated with argatroban, and 40 patients (46%) were not treated with argatroban. There was no association between argatroban therapy and bleeding, mortality, length of stay, or pretreatment thrombotic events. Among all patients, antiplatelet factor 4/heparin antibody titer and clinical probability score were higher in patients treated with argatroban. Conclusions: Clinical suspicion of heparin-induced thrombocytopenia as detected by clinical probability score and thrombotic complications should prompt immediate cessation of heparin and initiation of an alternative anticoagulant such as argatroban. The results from this study demonstrate that argatroban should be considered without increased risk for adverse events, including bleeding, in the cardiothoracic intensive care unit after surgery.
机译:目的:从心胸外科手术中康复的患者已知肝素诱发的血小板减少症的风险增加。术后,如果怀疑肝素诱导的血小板减少,应立即停用肝素,并使用其他抗凝剂,例如直接凝血酶抑制剂阿格曲班。在重症监护室中,有关argatroban在术后心胸外科手术患者中的安全性和有效性的最新数据有限。方法:回顾性收集2007年1月1日至2010年12月31日从抗心血因子4 /肝素抗体测试中被怀疑心胸手术后肝素诱发的血小板减少症患者的数据。我们通过比较血栓形成和出血事件,血小板动力学,抗血小板因子4 /肝素抗体滴度以及接受和未接受治疗的患者之间的临床概率评分,评估了Argatroban作为可疑肝素诱发的血小板减少症的术后治疗药物的用途阿加曲班。结果:87例患者被纳入研究。 47例(54%)患者接受了argatroban的治疗,40例患者(46%)未接受argatroban的治疗。阿加曲班治疗与出血,死亡率,住院时间或治疗前血栓形成事件之间没有关联。在所有患者中,接受argatroban治疗的患者的抗血小板因子4 /肝素抗体滴度和临床概率评分更高。结论:通过临床概率评分和血栓形成并发症检测到的肝素诱发的血小板减少症的临床怀疑,应促使肝素立即停药并开始使用替代抗凝药如阿加曲班。这项研究的结果表明,心胸重症监护室术后应考虑使用阿加曲班,而不会增加包括出血在内的不良事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号